Chirality in Chemistry and Biotechnology

What is Chirality?

Chirality arises when a molecule lacks an internal plane of symmetry, meaning it cannot be superimposed on its mirror image. These mirror-image forms are called enantiomers. Although enantiomers share identical physical properties such as melting point and solubility, they often exhibit different interactions with chiral environments—especially in biological systems. For example, one enantiomer of a drug may be therapeutically active, while the other could be inactive or even toxic. This is why chirality is a key consideration in drug development and regulatory compliance under standards such as ICH Q6A and ISO 17025.

Why Does Chirality Matter in Pharmaceuticals?

In biopharmaceuticals and small molecule drugs, chirality directly impacts efficacy, safety, and regulatory approval. Regulatory bodies such as the MHRA, EMA, and FDA require detailed characterisation of chiral compounds. Techniques like chiral HPLC, NMR with chiral solvating agents, and circular dichroism (CD) spectroscopy are routinely used to assess enantiomeric purity. The use of chiral synthesis or chiral separation methods ensures that final products meet strict specifications outlined in pharmacopoeias such as the British Pharmacopoeia (BP) and European Pharmacopoeia (EP).

How Is Chirality Controlled in Manufacturing?

Manufacturers employ chiral starting materials, chiral catalysts (e.g., in asymmetric synthesis), or chiral chromatography to produce enantiomerically pure compounds. Process validation and analytical control are essential to ensure consistent chirality throughout production. Deviations can lead to batch rejection, regulatory scrutiny, or safety incidents.

Related concepts

Chiral resolution, enantiomeric excess (ee), racemisation, stereoisomerism, asymmetric synthesis, chiral stationary phases.